JPMorgan Chase & Co. Reiterates “Neutral” Rating for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday, MarketBeat Ratings reports.

Other equities analysts have also issued reports about the company. Truist Financial increased their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Tuesday. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, BTIG Research raised their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Hold” and an average target price of $49.50.

Genmab A/S Trading Up 1.1 %

Shares of Genmab A/S stock opened at $27.49 on Tuesday. The firm has a market capitalization of $18.18 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. The business’s 50-day moving average price is $26.63 and its 200-day moving average price is $28.17. Genmab A/S has a 12 month low of $24.53 and a 12 month high of $39.53.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Point72 Asset Management L.P. purchased a new position in shares of Genmab A/S in the 2nd quarter valued at approximately $457,000. Cubist Systematic Strategies LLC increased its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after acquiring an additional 45,376 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.